Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
In a Phase 3 study, SB11 demonstrated equivalent efficacy in terms of change in best…
In a Phase 3 study, SB11 demonstrated equivalent efficacy in terms of change in best…
Designation based on phase 2 DESTINY-Lung01 This is the third Breakthrough Therapy Designation for ENHERTU,…
Acquisition to improve speed and agility of delivering advanced analytics, data and AI solutions to…
AHF urges the World Health Assembly at its virtual summit starting May 18 to put…
SINGAPORE--(BUSINESS WIRE)--SolarWinds (NYSE: SWI), a leading provider of powerful and affordable IT management software, has…
10% of respondents believe now is a good time to buy property, the highest percentage…
The report also uncovered a surge in activities from the threat actor group, APT32, in…
Aiming at new 5G services, such as one-stop solutions via local 5G systems TOKYO--(BUSINESS WIRE)--Mitsubishi…
Boutir benefits from iClick's 900+ million Chinese consumers' datasetsIncreases the technological sophistication of Boutir's ad…
CHICAGO & ZHENGZHOU CITY, China--(BUSINESS WIRE)--Trading Technologies International, Inc. (TT), a global provider of high-performance…